Core Insights - AbbVie Inc. announced that emraclidine failed in both phase 2 trials for schizophrenia patients, which is considered a shocking outcome in the biotech sector [2]. Company Summary - AbbVie Inc. (NYSE: ABBV) faced a significant setback with the failure of emraclidine in clinical trials, which may impact its future growth prospects and investor sentiment [2].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive has a presence in key finance and investing hubs with bureaus and studios located in major cities such as London, New York, and Sydney [2] Group 2 - The company utilizes technology to enhance workflows and has adopted automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [4]

Core Insights - AbbVie's Phase 2 EMPOWER trials for emraclidine did not achieve their primary endpoint of statistically significant improvement in PANSS total score compared to placebo at week 6 [1][2] - Emraclidine was well-tolerated, with an adverse event profile consistent with previous trials, indicating a safety profile comparable to Phase 1b trials [1][3] - AbbVie remains committed to analyzing the data for future steps and continues to focus on developing innovative therapies for psychiatric and neurological disorders [2][4] Clinical Trial Details - The EMPOWER clinical development program included two Phase 2 trials, EMPOWER-1 and EMPOWER-2, designed to evaluate emraclidine in patients with schizophrenia experiencing acute exacerbations [7][8] - The trials involved multiple dosing options to explore the therapeutic dose range for emraclidine [7] - A 52-week open-label extension trial, EMPOWER-3, is also part of the program, focusing on patients with stable symptoms [8] Emraclidine Overview - Emraclidine is a novel M4-selective positive allosteric modulator in development for schizophrenia and Alzheimer's disease psychosis, designed for once-daily administration without titration [6] - It selectively targets M4 muscarinic acetylcholine receptors to potentially reduce psychotic symptoms without blocking dopamine type 2 receptors, which are associated with many side effects of current antipsychotics [6] Neuroscience Focus - Neuroscience is a key area for AbbVie, which has expanded its pipeline through the acquisition of Cerevel, adding multiple clinical-stage and preclinical candidates to its existing portfolio [4][9] - AbbVie has a strong commitment to advancing treatment options for neurological and psychiatric disorders, supported by over three decades of experience in the field [9]

Core Viewpoint - High dividend yields can be misleading, but certain stocks like AbbVie, Gilead Sciences, and Pfizer present solid investment opportunities due to their strong fundamentals and consistent dividend growth [1][2]. AbbVie - AbbVie offers a 3.2% dividend yield, which is above average, and has consistently increased its dividend for years [3][4]. - The company announced a new quarterly dividend of $1.64 per share, reflecting a 5.8% increase, and has raised its quarterly dividend by 310% since its spin-off from Abbott Laboratories in 2013 [4][5]. - AbbVie generated $41.2 billion in sales over the past nine months, a 3% increase year-over-year, despite facing challenges with its top-selling drug Humira, which saw a 34% decline in sales this year [6][7]. Gilead Sciences - Gilead Sciences has a forward dividend yield of over 3.4%, significantly higher than the S&P 500 average of 1.3%, and has increased its dividends by 22.2% since late 2019 [9][10]. - The company has maintained revenue stability through its COVID-19 therapy Veklury and remains a leader in the HIV drug market with a 49% market share [10][11]. - Gilead is focusing on oncology, with over half of its 52 clinical programs dedicated to new cancer drugs or label expansions, indicating a strong pipeline for future growth [11][12]. Pfizer - Pfizer's forward dividend yield is currently at 6.1%, with a strong focus on maintaining and growing its dividend [13][14]. - The stock trades at approximately 9.2 times forward earnings, which is about half of the S&P 500 healthcare sector's forward earnings multiple [14]. - Despite potential challenges from patent expirations, Pfizer has a promising lineup of drugs and a robust pipeline with 108 programs in clinical development, including 30 in late-stage testing [15][16].

This Dividend King truly wears the crown.Certifications such as the Good Housekeeping Seal help consumers know which products are safe and perform well. Unfortunately, no Good Housekeeping Seal exists for dividend stocks.However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a company must increase its dividend for at least 50 consecutive years. Most income investors will sleep better at night knowing that a stock has such an impressive divid ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about AbbVie (ABBV) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.AbbVie currently has an average brokerage recommendation (ABR) of ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.If you're investing in stocks that have long track records for increasing their payouts, odds are, you're buying shares of them because of their stability and the potential for dividend income. But just because a stock is an excellent dividend investment doesn't mean it can't also be a top growth stock to own. Stocks that can balance both dividends and growth can give investors the best of b ...

Everybody loves dividends, as they provide a passive income stream, limit drawdowns in other positions, and provide more than one way to profit from an investment.And when considering dividend-paying stocks, those with a history of boosting their payout are prime considerations, reflecting their commitment to increasingly rewarding shareholders.In addition, consistent dividend hikes reflect the company’s successful nature, opting to share profits with shareholders.And recently, three companies – AbbVie (ABB ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's -0.5% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 4.8% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors ab ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35565 AbbVie Inc. (Exact name of registrant as specified in its charter) Delaware 32-0375147 (State or other jurisdiction o ...